chevron_left Categories

Other related webinars

Essential Regulatory Perspectives and Best Clini...

Monday, 7th February, 2011
Time : 01:00 PM EST | 10:00 AM PST

Biggest challenge for Pharmaceuticals/ Biotechno...

Tuesday, 22nd February, 2011
Time : 10:00 AM | 07:00 AM

Critical aspects of applying QbD to pharmaceutic...

Friday, 6th May, 2011
Time : 02:00 PM | 11:00 AM

Biologics Battlefield: Opportunities and Obstacl...

Thursday, 30th June, 2011
Time : 02:00 PM | 11:00 AM

Vital Success/Failure Regulatory Perspectives an...

Thursday, 15th September, 2011
Time : 02:00 PM | 11:00 AM

Good Laboratory Practices (GLP) Compliance and A...

Friday, 11th November, 2011
Time : 02:00 PM | 11:00 AM

Good Clinical Practice (GCP): FDA Regulations, S...

Thursday, 26th January, 2012
Time : 02:00 PM EST | 11:00 AM PST

Orphan Drugs in Europe – How to use observatio...

Friday, 1st June, 2012
Time : 02:00 PM EST | 11:00 AM PST

Implementing the Compliant Good Laboratory Pract...

Friday, 10th August, 2012
Time : 02:00 PM EST | 11:00 AM PST

An overview of an innovative patient-centric ser...

Wednesday, 12th September, 2012
Time : 02:00 PM EST | 11:00 AM PST

An overview of Translational Medicine

Friday, 21st September, 2012
Time : 02:00 PM EST | 11:00 AM PST

Optimizing Site Selection for Global Clinical Tr...

Friday, 26th October, 2012
Time : 02:00 PM EST | 11:00 AM PST

Optimal clinical supply planning for global drug...

Friday, 16th November, 2012
Time : 02:00 PM EST | 11:00 AM PST

Patient Recruitment & Retention Management in Cl...

Monday, 10th December, 2012
Time : 02:00 PM EST | 11:00 AM PST

GMP's for Dietary Supplements: Keys to Success w...

Thursday, 30th October, 2014
Time : 01:00 PM EST | 10:00 AM PST

Is It Safe? A Cautionary Tale and Practical Guid...

Friday, 9th January, 2015
Time : 02:00 PM EST | 11:00 AM PST

How To Reconcile ICH GCP With RISK BASED Monitor...

Thursday, 19th March, 2015
Time : 11:00 AM IST | 06:30 PM BET

Orphan Drugs : Regulation and Reimbursement Cond...

Friday, 22nd July, 2016
Time : 01:00 PM EST | 10:00 AM PST

Panel Discussion on Best Practices to Clinical T...

Friday, 10th March, 2017
Time : 04:00 PM IST | 11:30 AM BST

FDA Requirements for Good Clinical Practice’s ...

Friday, 7th July, 2017
Time : 04:00 PM IST | 11:30 AM BST

Implementation of Pharmaceutical Quality system ...

Friday, 17th November, 2017
Time : 01:00 PM EST | 10:30 AM PST

FDA Guidance for ICH GCP E6 R2 Means for Sponsor...

Thursday, 27th September, 2018
Time : 04:00 PM IST | 03:30 AM PDT

Managing Human Error in Quality Systems: Human E...

Friday, 17th July, 2020
Time : 01:00 PM EST | 10:00AM PST

FDA approvals of Orphan Drugs and Rare Diseases:...

Friday, 24th July, 2020
Time : 01:00 PM EST | 10:30 AM PST

FDA approvals of Orphan Drugs and Rare Diseases:...

Friday, 26th August, 2022
Time : 01:00 PM EST | 10:00 AM PST

Good Documentation Guideline (Chapter <1029> USP...

Friday, 11th November, 2022
Time : 01:00 PM EDT | 10:00 AM PST

FDA - Investigating OOS results

Friday, 17th March, 2023
Time : 01:00 PM EDT | 10:00 AM PDT

Best Practices for FDA's Investigating Deviation...

Friday, 26th May, 2023
Time : 01:00 PM EDT | 10:00 AM PDT

Recorded Webinar

Critical aspects of applying QbD to pharmaceutical process and product development for US Pharmaceutical Companies

timelapse 60 mins with 10-15 mins of Q and A

Note:

This webinar occured in the past
Along with recorded webinar, copy of presentation slides will be shared
Recorded Webinar can be played unlimited times

Speaker/Presenter

Short Abstract

“If the product is the process understanding both is critical for commercial success, a QbD approach is essential for process and product knowledge generation – the foundations that are being used for your product development will determine its success or failure – which do you chose knowledge or ignorance for the path forward”

Over the recent decade it is clear that the expected critical output in terms of regulatory agency expectations of product development is an in depth understanding of both the process and product characteristics. This is a foundational requirement upon which the complete product lifecycle is based. This encompasses the principles of Quality by Design (QbD), the heart of which is the idea that Quality, safety, and efficacy are designed or built into the product and that Quality cannot be adequately assured merely by in-process and finished-product inspection or testing. These are the fundamental concepts and once understood and accepted the QbD approach can become an integrated component of the overall process development effort. The process is logical and the underling concepts rational and yet adoption by industry is not without some resistance to change. Often the long term benefits are not well understood and shorter to mid-term business objectives become the key drivers, speed to market is the critical path. Which is a valid objective given the cost of product development and the need to return the investment? However consider the better investment of staying the complete course of the product lifecycle and not suffering a premature ending due to commercial manufacturing failures or out of control costs.

Still QbD is often viewed as a “means to an end” perhaps facilitating a speedier review by the regulatory agencies. Then the question might be is this worth the effort is the potentially longer process development times and higher cost offset by any strategic business and commercial benefit. Well the answer really is what worth knowledge, knowledge of process and product are invaluable in terms of firstly achieving approval to market the product and then keeping the product supplied to the market. This is not just a regulatory nice to have element it is the foundation upon which the whole product commercialisation can be built.


Apply for this webinar

Content Disclaimer

Contents in our website are from external websites. Links to and content from external website are provided for the convenience of users. Biopractice.com takes no responsibility for the content of such links and websites.

//